<DOC>
	<DOCNO>NCT00289562</DOCNO>
	<brief_summary>A Phase I/II , Multi-Center , Open-Label , Repeat-Dose Study Forodesine Hydrochloride Infusion Patients B-cell Acute Lymphoblastic Leukemia Option Extended Use Forodesine Hydrochloride</brief_summary>
	<brief_title>Forodesine Hydrochloride ( BCX-1777 ) B-Cell Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<criteria>Documented Bcell acute lymphoblastic leukemia ( BALL ) , WHO Guidelines refer precursor Blymphoblastic leukemia/lymphoma Must fail least 1 treatment regimen BALL , WHO Guidelines refer precursor Blymphoblastic leukemia/lymphoma Performance status â‰¤2 Eastern Cooperative Oncology Group ( ECOG ) criteria Any age allow Life expectancy least 3 month Adequate liver function ( aspartate transaminase [ AST ] and/or alanine transaminase [ ALT ] &gt; 3 time upper limit normal [ ULN ] ) Adequate kidney function ( calculated creatinine clearance &gt; 40 mL/min ) Negative serum urine pregnancy test within 2 7 day prior start study treatment female childbearing potential Females childbearing potential male must willing able use adequate method contraception avoid pregnancy duration study manner risk pregnancy minimize . Acceptable contraceptive include intrauterine device ( IUDs ) , hormonal contraceptive ( oral , depot , patch , injectable ) double barrier method condom diaphragms spermicidal gel foam . Signed informed consent form ( ICF ) , minor assent form ( applicable ) , prior start studyspecific procedure Active serious infection control oral intravenous antibiotic Treatment investigational antileukemic agent chemotherapy agent last 7 day prior study entry lack full recovery side effect due prior therapy independent therapy give Rapidly progressive disease compromise organ function judge lifethreatening Investigator Patients clinical evidence active central nervous system ( CNS ) disease Concurrent treatment anticancer agent Pregnant and/or lactate female Patients know human immunodeficiency virus ( HIV ) infection HIV testing perform Screening visit patient test within 6 month receive study drug , well patient exposure transfuse blood product appropriately screen . Patients know active hepatitis B and/or hepatitis C infection Hepatitis testing perform Screening visit patient test within 6 month receive study drug , well patient exposure transfuse blood product appropriately screen . Hypersensitive intolerant component study drug formulation</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>B-cell</keyword>
	<keyword>leukemia</keyword>
	<keyword>B-lymphoblastic leukemia</keyword>
	<keyword>lymphoma</keyword>
	<keyword>B-All</keyword>
</DOC>